Skip to main contentSkip to navigation
Sirius Investors

VRAX Stock: Virax Biolabs Group Limited Stock Price, Analysis & Insights

Get live VRAX stock price $0.19, comprehensive Virax Biolabs Group Limited stock analysis, charts, news, and expert forecast. Real-time VRAX stock data and investment insights.

0.19
9.87%Today
VRAXVirax Biolabs Group Limited • NASDAQ Capital Market • Healthcare
Market Cap
817.16K
Volume
1.23M
52W High
1.14
52W Low
0.10

Loading chart data...

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Virax Biolabs Group Limited is a biotechnology firm that specializes in the sale, distribution, and promotion of diagnostic testing kits, medical technology, and personal protective equipment (PPE). Its offerings are designed to aid in the prophylaxi...

Company Information

CEO
James Foster
Sector
Healthcare
Industry
Biotechnology
Employees
17

Contact Information

Address
30 Broadwick Street
Country
GB

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Higher growth potential with elevated volatility (Beta: 1.24)

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Virax Biolabs Group Limited shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Virax Biolabs Group Limited
  • Investors should consider how Virax Biolabs Group Limited fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

817.16K

P/E Ratio (TTM)

-0.15

Beta

1.24

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.